RLAY News and Press, Relay Therapeutics Inc. From 11/30/20

Kinnate Biopharma aims to raise $170 million in an IPO. The firm is developing kinase inhibitor-based treatment candidates for various cancers. KNTE has produced promising results in preclinical studies, but is still extremely high risk; the IPO may be more suited to long-term hol...

Relay Therapeutics (RLAY): Q3 GAAP EPS of -$3.00.Cash, cash equivalents and investments of $713M. Press Release For further details see: Relay Therapeutics reports Q3 results

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today reported third quarter 2020 financial results. ...

Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each. For further details see: These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference

Relay Therapeutics ([[RLAY]] +7.3%) is up, albeit on below-average volume, in apparent response to a presentation on the company by fundamental shop EcoR1 Capital at the Sohn Conference.The company debuted on July 16 at $20. Shares are currently exchanging hands at $47.13, up 136%.It develops...

Investment Thesis Relay Therapeutics share price performance since IPO (Source: TradingView ) Investors looking to place a bet on the next big biotech trend may want to take a close look at Relay Therapeutics ( RLAY ), a novel drug discovery startup with a strong management team, ac...

Relay Therapeutics (NASDAQ: RLAY ) has dosed the first patient in a first-in-human  clinical trial of RLY-4008 enriched for patients with intrahepatic cholangiocarcinoma (ICC) and other advanced solid tumors harboring a fibroblast growth factor receptor 2 (FGFR2) alteration. ...

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced the first patient has been dosed in a fi...

This is the 3rd article in a 4-part series on Israel-based Evogene Ltd. ( EVGN ). This article will focus on Evogene's 100% owned subsidiary AgPlenus. For more information about Evogene, I invite you to read the first two articles in this 4-part Evogene series which were published on Seeking...

Relay Therapeutics (NASDAQ: RLAY ) : Q2 GAAP EPS of -$6.06 misses by $5.03 . Cash, cash equivalents and investments totaled $312M as of June 30, 2020 $312M Press Release More news on: Relay Therapeutics, Inc., Earnings news and commentary,